Condition

IgA Nephropathy clinical trials and research

• 16Clinical trials
• 7NIH research projects
• 13Countries

Newest IgA Nephropathy clinical trials

All recruiting trials (16)

• JADE101 in IgA Nephropathy: a Phase 2 test in adults

  This Phase 2 open-label study tests JADE101 in adults with IgA nephropathy to see how safe it is and how well it works when added to standard care.

  Recruiting at 22 sites Phase 2 Jade Biosciences, Inc. · Chula Vista, California and 21 other locations · NCT07541287

• Atrasentan for pediatric primary IgA nephropathy

  This study tests whether atrasentan can help children and teens with primary IgA nephropathy reduce protein in urine.

  Recruiting at 19 sites Phase 3 Novartis · Neptune City, New Jersey and 22 other locations · NCT07498335

• Anti-CD19/BCMA universal CAR-T (RD06-05) for autoimmune diseases

  This early-phase test gives a universal CAR-T therapy (RD06-05) that targets CD19 and BCMA to adults with autoimmune diseases such as SLE/lupus nephritis, ANCA-associated vasculitis, and anti-GBM disease.

  Recruiting Early Phase 1 Nanjing Bioheng Biotech Co., Ltd. · Shanghai, Shanghai Municipality · NCT07203404

• BHV-1400 for IgA nephropathy

  This study will try BHV-1400 in adults with biopsy-confirmed IgA nephropathy to see if the drug is safe and tolerable.

  Recruiting at 15 sites Phase 1 Biohaven Pharmaceuticals, Inc. · Farmington, Connecticut and 14 other locations · NCT07054684

• Nefecon (budesonide) plus ambrisentan for IgA nephropathy with proteinuria

  This test will see if combining Nefecon (a gut‑targeted budesonide) with ambrisentan can reduce urine protein and slow kidney decline in adults with IgA nephropathy who have at least 0.5 g of protein in a 24‑hour urine collection.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07030894

• Epithelial Dysmetabolism and Kidney Fibrosis in ANCA Vasculitis

  This study tests whether alterations in tubulo-interstitial metabolism relate to how quickly kidney function deteriorates in people with ANCA-associated vasculitis compared to other nephropathies.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07010250

• Which approved add-on drugs slow kidney decline in South-Asian adults with biopsy-proven IgA nephropathy?

  This trial will test whether adding one of several approved oral medications to standard care can slow kidney function loss over two years in South-Asian adults with biopsy-proven IgA nephropathy.

  Recruiting Phase 4 Christian Medical College, Vellore, India · Nadiād, Gujarat and 11 other locations · NCT06676384

• ADX-097 in IgA Nephropathy, Lupus Nephritis, or C3 Glomerulopathy

  This phase 2 study tests whether subcutaneous ADX-097 can be safely tolerated and show clinical activity in people 16 or older with IgAN, LN, or C3G.

  Recruiting at 3 sites Phase 2 Akebia Therapeutics · Hollywood, Florida and 3 other locations · NCT06419205

• Hydroxychloroquine for IgA Nephropathy: See If It Helps Manage the Disease

  This study tests whether hydroxychloroquine can help people with IgA nephropathy, to see if it reduces kidney damage and protein in the urine.

  Recruiting at 8 sites Phase 2 Centre Hospitalier Universitaire de Saint Etienne · Clermont-Ferrand and 7 other locations · NCT06350630

• National Registry for Rare Kidney Diseases

  This study is collecting health information from people with rare kidney diseases to help improve treatments and create better care guidelines.

  Recruiting UK Kidney Association · Bristol, South West · NCT06065852

• Treatment of IgA Nephropathy with CM338

  This study is testing a new treatment called CM338 to see if it can help people with IgA nephropathy manage their kidney disease better.

  Recruiting Phase 2 Keymed Biosciences Co.Ltd · Beijing, Beijing Municipality · NCT05775042

• Exploring the link between gut bacteria and IgA Nephropathy

  This study is trying to see how gut bacteria and their byproducts affect people with IgA Nephropathy to help improve early diagnosis and treatment of the disease.

  Recruiting at 5 sites Guangdong Provincial People's Hospital · Guangzhou, Guangdong and 4 other locations · NCT05190848

• Registry for patients with IgA Nephropathy

  This study is creating a registry for people with IgA nephropathy in China to help improve diagnosis and treatment by collecting and organizing important health information.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT04858724

• A network for analyzing kidney biopsy data in glomerular diseases

  This study is trying to build a detailed database of kidney biopsy samples and health information from patients with glomerular diseases to help researchers better understand these conditions and improve treatments.

  Recruiting at 6 sites Seoul National University Hospital · Chuncheon and 5 other locations · NCT03929887

• Registering patients with IgA nephropathy in China

  This study is trying to gather information from patients with IgA nephropathy in China to see how the condition affects their long-term health and outcomes.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT03001947

• Evaluating biomarkers in IgA nephropathy patients

  This study is trying to see if certain blood and urine markers can help predict how kidney disease will progress in people with IgA nephropathy who still have normal kidney function.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT02954419

NIH-funded research (7)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Understanding how IgA1 immune complexes cause kidney disease in Berger’s disease

  This grant studies the specific features of abnormal IgA1 immune complexes that drive kidney damage in IgA nephropathy to pave the way for better diagnosis and treatment.

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-11431374

• Genetics of IgA nephropathy through network-based genetic links

  A study to understand why some people develop IgA nephropathy by looking at how our genes and immune system networks contribute to the disease.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11393618

• B cells that make abnormal IgA1 in IgA kidney disease

  Researchers are identifying a group of B cells that produce a harmful form of IgA1 in people with IgA nephropathy to help guide future treatments.

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-11235941

• Genetic drivers of IgA (Berger's) kidney disease

  This project looks for gene changes that make people more likely to get IgA (Berger's) kidney disease.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11121895

• A new way to identify IgA nephropathy using specific markers

  This project aims to create better blood tests for IgA nephropathy, a kidney disease, by looking for specific immune markers.

  NIH research Reliant Glycosciences LLC · Birmingham, United States · NIH-11120925

• Identifying specific B cells linked to a kidney disease called IgA nephropathy

  This study is looking at a special type of immune cell that makes a form of IgA linked to IgA nephropathy, to better understand how it contributes to kidney problems, with the hope of finding new treatments for people with this condition.

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-10978234

• Investigating how EBV infection affects racial differences in IgA nephropathy

  This study is looking at how the Epstein-Barr virus might be linked to IgA nephropathy, a kidney disease, and it wants to understand why this condition affects some racial groups more than others, so if you're a patient, you might be asked to share a blood sample and some health details to help with this important rese

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-10661504

Related topics

Quick answers

How many IgA Nephropathy clinical trials are recruiting right now?

16, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 13 countries. The most sites are in China (8 trials), United States (4 trials), France (3 trials), South Korea (3 trials), United Kingdom (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 4: 2, Phase 1: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →